BRIEF published on 11/21/2025 at 11:25, 2 months 8 days ago Crossing of thresholds by Samsara BioCapital at INVENTIVA Voting Rights Capital Increase Threshold Crossing Inventiva Samsara BioCapital
PRESS RELEASE published on 11/13/2025 at 15:21, 2 months 16 days ago Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares
BRIEF published on 11/13/2025 at 08:45, 2 months 17 days ago Inventiva Announces Temporary Trading Halt on Euronext Paris Euronext Paris Nasdaq Trading Halt Inventiva ADS Offering
PRESS RELEASE published on 11/13/2025 at 08:40, 2 months 17 days ago Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris Inventiva temporarily halts trading of ordinary shares on Euronext Paris for public offering preparation, with expected resumption by end of day. Company focuses on MASH treatment research Euronext Paris Trading Halt Public Offering Inventiva MASH Treatment
BRIEF published on 10/14/2025 at 22:05, 3 months 15 days ago Inventiva Launches New ATM Program to Raise $100 Million Biopharmaceutical SEC Filing Inventiva Lanifibranor ATM Program
PRESS RELEASE published on 10/14/2025 at 22:00, 3 months 15 days ago Inventiva Announces the Implementation of a New ATM Program Inventiva implements new ATM program, files Registration Statement with the SEC for up to $100 million aggregate gross sales proceeds. Proceeds to fund research and development, working capital, and corporate purposes Biopharmaceutical SEC Registration Statement Inventiva ATM Program
BRIEF published on 10/07/2025 at 22:05, 3 months 22 days ago Inventiva at Liver Meeting 2025: Key Presentations on Lanifibranor Digital Pathology Inventiva MASH Lanifibranor Liver Meeting 2025
PRESS RELEASE published on 10/07/2025 at 22:00, 3 months 22 days ago Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025 Inventiva to present multiple abstracts at AASLD The Liver Meeting® 2025 showcasing digital pathology data and therapeutic benefits of lanifibranor in MASH treatment. Visit booth #745 for more Digital Pathology Inventiva MASH Lanifibranor AASLD The Liver Meeting
BRIEF published on 10/01/2025 at 08:35, 3 months 29 days ago Andrew Obenshain Appointed as CEO of Inventiva Leadership Transition Drug Development Inventiva MASH Treatment Andrew Obenshain
PRESS RELEASE published on 10/01/2025 at 08:30, 3 months 29 days ago Inventiva Appoints Andrew Obenshain as Chief Executive Officer Inventiva appoints Andrew Obenshain as Chief Executive Officer, succeeding Frédéric Cren, to lead company's growth and prepare for potential commercialization in the United States Chief Executive Officer Inventiva MASH Frédéric Cren Andrew Obenshain
Published on 01/30/2026 at 08:35, 1 hour 31 minutes ago Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 2 hours 6 minutes ago Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 7 hours 51 minutes ago Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 10 hours 6 minutes ago LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Published on 01/29/2026 at 23:00, 11 hours 6 minutes ago PPX Mining Announces Filing of 2025 Audited Financial Statements and MD&A
Published on 01/30/2026 at 09:00, 1 hour 5 minutes ago Original-Research: 123fahrschule SE (von NuWays AG): BUY
Published on 01/30/2026 at 09:00, 1 hour 5 minutes ago Original-Research: q.beyond AG (von NuWays AG): BUY
Published on 01/30/2026 at 08:00, 2 hours 6 minutes ago Ørsted to present its annual report for 2025 on February 6
Published on 01/29/2026 at 18:00, 16 hours 6 minutes ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 16 hours 21 minutes ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 16 hours 21 minutes ago Cegedim generated LFL revenue growth of 1.1% in 2025
